"New COVID-19 Vaccine Demonstrates 54% Efficacy Against Symptomatic Infection, Early CDC Data Reveals"

Early CDC data suggests that the latest Covid-19 vaccine provides 54% protection against symptomatic infection, including from the JN.1 variant, which has been predominant in the US since late December. The analysis, based on over 9,000 adults, indicates that the vaccines are effective in the general population, although waning protection over time is expected. Despite high levels of Covid-19 circulation and hospitalizations, only a fraction of the population has received the latest vaccine, which is recommended for everyone aged 6 months and older.